Exploring the Impact of Treatment Switching on Overall Survival from the PROfound Study in Homologous Recombination Repair (HRR)-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Rachel EvansNeil HawkinsPascale Dequen-O'ByrneCharles McCreaDominic MustonChristopher GrestySameer R GhateLin FanRobert HettleKeith R AbramsJohann de BonoMaha HussainNeeraj Agarwal

Published in: Targeted oncology (2021)

The magnitude of the statistically significant (P < 0.05) survival benefit of olaparib versus control observed in Cohort A of PROfound is likely to be underestimated if adjustment for treatment switching from control to olaparib is not conducted. The RPSFTM was considered the most plausible method, although further development and validation of robust methods to estimate the magnitude of impact of treatment switching is needed.

Keyphrases

small cell lung cancer
dna damage
squamous cell carcinoma
intellectual disability
oxidative stress
autism spectrum disorder